drugset / Trial / NCT00035854

New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)

NCT00035854 ↗

Phase 3 Completed 13 enrolled Pfizer
RandomizedSingle-groupOpen-labelTreatment

Summary

This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)

Timeline

Start
2002-02
Primary completion
—
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Linezolid Other / unclassified — Intravenous